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Abstract
Introduction: Human induced pluripotent stem cells (hiPSCs) are considered as one of the most promising seed
cell sources in regenerative medicine. Now hiPSC-based clinical trials are underway. To ensure clinical safety, cells
used in clinical trials or therapies should be generated under GMP conditions, and with Xeno-free culture media to
avoid possible side effects like immune rejection that induced by the Xeno reagents. However, up to now there are
no reports for hiPSC lines developed completely under GMP conditions using Xeno-free reagents.
Methods: Clinical-grade human foreskin fibroblast (HFF) cells used as feeder cells and parental cells of the
clinical-grade hiPSCs were isolated from human foreskin tissues and cultured in Xeno-free media. Clinical-grade
hiPSCs were derived by integration-free Sendai virus-based reprogramming kit in Xeno-free pluriton™ reprogramming
medium or X medium. Neural cells and cardiomyocytes differentiation were conducted following a series of spatial
and temporal specific signals induction according to the corresponding lineage development signals. Biological safety
evaluation of the clinical-grade HFF cells and hiPSCs were conducted following the guidance of the “Pharmacopoeia
of the People's Republic of China, Edition 2010, Volume III”.
Results: We have successfully derived several integration-free clinical-grade hiPSC lines under GMP-controlled
conditions and with Xeno-free reagents culture media in line with the current guidance of international and national
evaluation criteria. As for the source of hiPSCs and feeder cells, biological safety evaluation of the HFF cells have been
strictly reviewed by the National Institutes for Food and Drug Control (NIFDC). The hiPSC lines are pluripotent and have
passed the safety evaluation. Moreover, one of the randomly selected hiPSC lines was capable of differentiating into
functional neural cells and cardiomyocytes in Xeno-free culture media.
Conclusion: The clinical-grade hiPSC lines therefore could be valuable sources for future hiPSC-based clinical trials or
therapies and for drug screening.
Introduction
Human pluripotent stem cells (hPSCs) can differentiate
into any type of cells in the body, such as functional neural
progenitor cells or cardiomyocytes, and therefore have
enormous value in regenerative medicine. The increasing
incidence of degenerative diseases, limitations of traditional
therapeutic methods, and the shortage of isolated human
functional cells have urged scientists to turn to stem cell-
based cell replacement therapies. Although the translation
from basic discoveries to clinical settings comes with great
challenges, intensive stem cell-based clinical trials are
emerging from around the world. For human embryonic
stem cells (hESCs), a clinical trial of spinal-cord injury
treatment using immature glial cells derived from hESCs by
the Geron Corporation (Menlo Park, California, USA) has
recommenced after it was brought to a halt in 2011 [1].
Another clinical trial of hESCs involving the generation of
retinal pigmented epithelial (RPE) cells for the treatment of
eye disorders such as Stargardt’s macular dystrophy, myopic
* Correspondence: liu086@163.com; zhouqi@ioz.ac.cn
†Equal contributors
2College of Life Science, Northeast Agricultural University of China, Harbin
150030, China
1State Key of Stem Cells and Laboratory of Reproductive Biology, Institute of
Zoology, Chinese Academy of Sciences, Beijing 100101, China
Full list of author information is available at the end of the article
© 2015 Wang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wang et al. Stem Cell Research & Therapy  (2015) 6:223 
DOI 10.1186/s13287-015-0206-y
macular degeneration, and advanced dry age-related macu-
lar degeneration is currently being conducted by the
Advanced Cell Technology company (Marlborough,
Massachusetts, USA) in America [2]. The mid-term out-
comes confirmed the safety and efficacy of hESC-derived
RPE in patients [3]. When taking moral and ethical aspects
into consideration, human induced pluripotent stem cells
(hiPSCs) are more ideal and feasible cell sources for
transplantation compared with hESCs. A clinical trial for
eye disorder treatment using hiPSC-derived RPE cells is
also now being carried out in Japan [4].
Initially, the generation of hiPSCs involved integrated
retrovirus expressing Oct4, Sox2, Klf4, and c-Myc [5, 6].
However, random integrations may result in insertional
mutagenesis consequently risking patients’ safety. Also,
unexpected activation of the integrated oncogene c-Myc
may initiate tumorigenesis [7]. To circumvent the aforemen-
tioned problems, integration-free hiPSCs have been gener-
ated using Sendai viruses [8], episomal vectors [9], mRNAs
[10], minicircle DNAs [11], microRNAs [12], and proteins
[13]. Although each method has its own merits and disad-
vantages, integration-free reprogramming methods are
optimal for future clinical applications.
Most of the hESC lines collected by the National Insti-
tutes of Health (NIH) have been reported ineligible for
future therapeutic products use because their derivation
processes did not follow the “Tissue Donor Guidance” [14].
Precautionary actions are therefore of utmost importance
in order to ensure the safety, effectiveness, traceability, re-
producibility, and legality of hiPSCs intended for clinical tri-
als or therapies. Careful screening for legal and eligible
donors is a very important step. According to the current
national and international regulation policies, most coun-
tries require a good manufacturing practice (GMP) envir-
onment when handling the cells [15, 16]. Reagents used in
the culture process will greatly affect the safety and quality
of the cells. Xeno reagents would not only increase the risk
of infections but also cause immune rejection upon cell
transplantation [17]. Almost all countries have advocated
that animal reagents should not be used in cells for clinical
applications [18]. Therefore it is sensible to use Xeno-free
reagents in all cell handling processes. To further ensure
the safety of the cells used in clinical settings, endotoxin
and serious pathogenic microorganism such as myco-
plasma and HIV virus have to be tested [19].
We define hiPSCs intended to be used for potential
clinical applications as clinical-grade hiPSCs. Theoretic-
ally, clinical-grade hiPSCs should meet the following
requirements. First, parental cell donors should meet
the requirements of the “Tissue Donor Guidance”.
Second, the cell handling processes should be conducted
under GMP-controlled environments and with Xeno-free
reagents. Third, the derived clinical-grade hiPSCs should
be integration-free and biologically safe.
Previously, a group reported the derivation of hiPSCs
under fully defined conditions. However, the biological
safety of the obtained hiPSC lines is questionable. Fur-
thermore, the group did not describe whether their
protocol was within the “Tissue Donor Guidance” [20].
Several other groups have also successfully achieved the
so-called clinical-grade hiPSC lines by converting the
existing nonclinical-grade hiPSC lines. Still, in these
processes animal products were applied in the initial
stages, which may confer risks of cross-species infectious
agent transfer [21–23]. For these reasons, there is an
urgent need to derive clinical-grade hiPSC lines strictly
following all requirements of clinical-grade hiPSCs.
Here, we report successful generation of several clinical-
grade hiPSC lines. A series of pathogenic microorganism
tests were conducted on foreskin tissue donors according
to the “Tissue Donor Guidance” of China. The human
foreskin fibroblast (HFF) cells used for reprogramming
and as feeder cells were isolated and cultured using Xeno-
free reagents in a GMP-grade laboratory and were con-
firmed negative for mycoplasma and certain pathogenic
microorganisms. Furthermore, the biological safety of the
HFF cells is validated by the National Institutes for Food
and Drug Control (NIFDC). All processes of the hiPSC
generation were conducted under GMP-controlled condi-
tions using Xeno-free media and reagents. The resulting
hiPSCs are validated as integration-free, and are able to
randomly differentiate into three germ layers in vitro and
in vivo as well as directly differentiate into functional
neural cells and cardiomyocytes in Xeno-free media. The
biological safety of these hiPSCs is further validated. These
hiPSC lines, generated following all of the requirements of
clinical-grade hiPSCs strictly, might serve as valuable cell
sources for future clinical applications.
Methods
Ethical approval
The foreskin tissues were donated by males undergoing
foreskin operation in Beijing Children’s Hospital with the
approval of the Animal and Medical Ethics Committee of
Institute of Zoology, Chinese Academy of Sciences. Writ-
ten consent was obtained from the donors’ parents. The
content of the consent includes the potential use of cells
derived from the foreskin (research or potential clinical
therapies) and the rights and obligations of the donors.
After donation, a thorough assessment of the donors’
medical history and infectious diseases were performed.
Based on the results, donors were selected. All informa-
tion is secured to protect the privacy and confidentiality
of donors. No financial benefits were involved in the do-
nation process. All cell isolation and culture procedures
followed closely the guidelines legislated and posted by
the Ministry of Health of the People’s Republic of China.
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All animal experiments were approved in advance by
the Animal and Medical Ethics Committee of Institute
of Zoology, Chinese Academy of Sciences.
Isolation of fibroblasts from foreskin tissues
Foreskin tissues were collected into 50 ml centrifuge tubes
containing Dulbecco's Phosphate Buffered Saline (DPBS)-
CTS (Life Technologies, Carlsbad, California, USA) and
transported to the laboratory on ice. After sufficient wash-
ing with DPBS-CTS, fat and connective tissues were re-
moved from the foreskin. The foreskin was then cut into
small pieces with a volume of about 1 mm3 and transferred
to T75 flasks precoated with MesenCult-XF attachment
substrates (Stem Cell Technologies, Vancouver, British
Columbia, Canada) without cell culture medium. After
24 hours of inverted culturing in a humidified incubator
(at 37 °C, 5 % CO2), 4 ml FibroGRO™ Xeno-Free Hu-
man Fibroblast Expansion Medium (Millipore, Billerica,
Massachusetts, USA) was added to each flask. After 7
days of culture, fibroblasts could outgrow the tissues
and be routinely passaged. The obtained fibroblasts were
used as parental cells for hiPSC induction and as feeder
cells after being irradiated with gamma rays.
Cell culture
HFF cells were cultured in FibroGRO™ Xeno-Free Human
Fibroblast Expansion Medium (Millipore) on dishes pre-
coated with Mesencult-XF attachment substrates accord-
ing to the manufacturer’s instructions. Clinical-grade
hiPSCs were initially cultured on gamma ray-inactivated
human feeder cells in pluriton™ reprogramming medium
(Stemgent, Lexington, Massachusetts, USA) or X medium
(configured in our laboratory). The formulations of X
medium were as follows: clinical-grade hESC basic
medium and clinical-grade N2B27 medium mixed at 1:1
ratio supplemented with 10 ng/ml human leukemia in-
hibitory factor (hLif; Peprotech) and human basic fibro-
blast growth factor (bFGF; Peprotech, Rocky Hill, Rocky
Hill, USA). The clinical-grade hESC basic medium con-
tained knockout Dulbecco’s modified Eagle’s medium
(DMEM)-CTS (Life Technologies), 20 % knockout
serum replacement (KOSR)-CTS (Life Technologies),
100 μM none essential amino acid (NEAA; Life Technolo-
gies), 2 mM GlutaMAX-CTS (Life Technologies), 55 μM
β-mercaptoethanol (Life Technologies), and 1000 U/ml
penicillin/streptomycin (Life Technologies). The clinical-
grade N2B27 medium was a mixture of knockout DMEM-
CTS supplemented with N2-CTS (Life Technologies) and
Neurobasal Medium-CTS (Life Technologies) supple-
mented with B27-CTS (Life Technologies) at 1:1 ratio plus
100 μM NEAA, 2 mM GlutaMAX-CTS, 55 μM β-
mercaptoethanol, and 1000 U/ml penicillin/streptomycin.
At passages 10–12, the cells were transferred to E8
medium (Life Technologies) without feeder cells.
Induction of hiPSCs from HFF cells
HFF cells were cultured in six-well sterile culture plates
precoated with MesenCult-XF Attachment Substrate in
FibroGRO™ Xeno-Free Human Fibroblast Expansion
Medium without antibodies. The CytoTune®-iPS Sendai
Reprogramming Kit (Life Technologies) was used for
deriving integration-free iPSCs according to the manufac-
turer’s instructions. The medium used in the reprogram-
ming process was pluriton™ reprogramming medium or X
medium. Colonies with typical hPSC morphology were
picked 20 days post transduction for further expansion.
Alkaline phosphatase staining
Alkaline phosphatase staining was performed using the
Alkaline Phosphatase Assay Kit (Beyotime, Shanghai,
China) according to the manufacturer’s instructions.
Immunofluorescence staining
Immunofluorescence staining was conducted as described
previously [23]. The primary antibodies used were OCT4
(1:200; Santa, Dallas, Texas, USA), SOX2 (1:200; Millipore),
SSEA-1 (1:200; Millipore), SSEA-3 (1:200; Millipore), SSEA-4
(1:200; Millipore), TH1 (1:400; Millipore), TUJ1 (1:1000;
Covance, Princeton, New Jersey, USA), NKX2.5 (1:200;
Abcam, Cambridge, UK), and CTNT (1:200; R&D, Minneap-
olis, Minnesota, USA). The secondary antibodies were donkey
anti-mouse IgG (H+L) conjugated to Cy3 (1:200; Jackson,
Lansing, Michigan, USA), donkey anti-mouse IgG conjugated
to Cy5 (1:200; Jackson), donkey anti-goat IgG conjugated to
Cy5 (1:200; Jackson), donkey anti-rabbit IgG conjugated
to fluorescein isothiocyanate (FITC) (1:200; Jackson), and
donkey anti-rat IgG conjugated to Cy5 (1:200; Jackson).
Karyotyping and G-binding
When hiPSCs reached 60–70 % confluency, karytoyping
and G-binding analysis were carried out by Chinese Acad-
emy of Medical Science & Peking Union Medical College.
RNA isolation, reverse transcription and PCR analysis
RNA isolation and reverse transcription were performed as
described previously [24]. Real-time PCRs were conducted
with the SYBR® Premix EX Taq™ kit (Takara, Minamiku-
satsu Station, Japan) and Agilent, Santa Clara, California,
USA, Mx3005P equipment according to the manufac-
turer’s instructions. Normal PCR reactions were conducted
according to the previous report [24]. Primer sequences
used in the experiments are presented in Additional file 1.
Embryoid body formation assay
The embryoid body (EB) formation assay was conducted
as described previously [24] with the exception of using
Xeno-free ethylenediamine tetraacetic acid (EDTA; Life
Technologies) for cell dissociation and clinical-grade
hESC basic medium for EB culture.
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Teratoma formation assay
Confluent cells in a six-well plate were harvested using
EDTA and suspended in DPBS-CTS. Then 106 cells in
20–30 μl DPBS were injected into each testis of severe
combined immunodeficiency (SCID) mouse under a sterile
stereo microscope. The mice were sacrificed 8 weeks after
injection for teratoma examination following the guidelines
of the Institutional Animal Care and Use Committee
(IACUC). The teratomas were fixed, sliced, and stained
with hematoxylin and eosin for further analysis.
Neural cell differentiation
Neural cell differentiation was performed as described
previously [25] apart from the media used being Xeno-free
in all processes. Briefly, confluent hiPSCs were dissociated
into single cells by tryple-CTS (Life Technologies) and
plated on Vitronectin-coated dishes at a density of 4 × 105
cells/cm2 on day 0. Initially, the cells were cultured in a
medium of knockout DMEM-CTS supplemented with
15 % KOSR-CTS, 100 μM NEAA, 2 mM GlutaMAX-CTS,
55 μM β-mercaptoethanol, and 1000 U/ml penicillin/strepto-
mycin. On day 5, the medium containing KOSR-CTS was
gradually transitioned to N2 medium-CTS as described pre-
viously [25]. On day 11, the medium was changed to Neuro-
basal medium-CTS supplemented with 2 % B27-CTS. To
induce differentiation, growth factors and small molecules
were added as follows: 10 μM SB431542 (Stemgent) from
day 0 to 5, 100 nM LDN93189 (Stemgent) from day 0 to 11,
3 μM CHIR99021 from day 3 to 13, 100 ng/ml SHH C25II
(R&D), 2 μM purmorphamine (Stemgent), and 100 ng/ml
FGF8 (R&D) from day 1 to 7, and 20 ng/ml brain-derived
neurotrophic factor (BDNF; R&D), 0.2 mM ascorbic acid
(Sigma, Louis, Missouri, USA), 20 ng/ml glial cell line-
derived neurotrophic factor (GDNF; R&D), 1 ng/ml trans-
forming growth factor type β3 (TGFβ3; R&D), 0.5 mM
dibutyryl cAMP (Sigma), and 10 μM (DAPT) N-[(3,5-
Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethy-
lethyl ester (Tocris, Bristol, Bristol, UK) from day 11 to 23.
Cardiomyocyte differentiation
Confluent hiPSCs were digested into single cells by
accutase (Life Technologies) and seeded on vitronectin-
coated dishes at a density of 1.25 × 105 cells/cm2. Then
the cells were grown in E8 medium for 2–3 days to
reach 100 % confluency. To improve the efficiency of
single cell survival, 10 μM Y27632 were added on the
first day. Culture medium used in the differentiation
process was RPMI 1640 (Life Technologies) with a com-
bination of chemically defined components (modified in
our laboratory and data not published) which we named
Car-CDM. From day 0 (the day for differentiation
medium adding) to day 8, Car-CDM without insulin was
used as differentiation medium. In this period, the
medium was changed on days 0, 1, 3, and 5. From day 0
to 1, 4 μM were added, whereas 2 μM Wnt-C59 (Sigma)
was added from day 3 to 8 (Sigma). From day 8 onward,
the differentiation medium was changed to Car-CDM
plus insulin and the medium was changed every other
day up to day 14. Beating cardiomycytes generally ap-
peared on day 12 of differentiation.
Endotoxin testing
Endotoxin testing was performed using the ToxinSensor™
Gel Clot Endotoxin Assay Kit (GeneScript, Piscataway, New
Jersey, USA) according to the manufacturer’s instructions.
Mycoplasma testing
Mycoplasma testing was performed using the PlasmoTest™
Reagent Kit (InvivoGen, San Diego, California, USA) ac-
cording to the manufacturer’s instructions.
Pathogenic microorganism testing
The defined pathogenic microorganisms tested were hu-
man papilloma virus (HPV), human parvovirus B19, hu-
man immunodeficiency virus (HIV), John Cunningham
virus (JCV), Epstein–Barr virus (EBV), human hepatitis
C virus (HCV), human hepatitis A virus (HAV), human
cytomegalovirus (HCMV), human T-lymphotropic virus
I (HTLV-I), human hepatitis B virus (HBV), bovine
virus, and porcine virus. These viruses were detected
using corresponding kits produced by Zhongshandaan
Company, Guangzhou, Guangdong, China. Some of the
viruses were reviewed by Beijing Ai Puyi Medical Test-
ing Center, Beijing, China. The hiPSCs were also inocu-
lated into the chorioallantoic membrane and yolk sac of
chicks according to the methods described in the
Chinese Pharmacopoeia (third edition).
Results
Preparations for generation of clinical-grade hiPSCs
Safety, traceability, and reproducibility are three basic criteria
for cells to be used in clinical trials or therapies. To meet
these criteria, GMP environments are required for the whole
process of cell manipulation. We have established a GMP-
controlled cell culture laboratory and it has passed the
Beijing Institute for Drug Control (Beijing Center for Health
Food and Cosmetics Control) test. The room was cleaned
and tested regularly to ensure its cleanliness (Fig. 1).
The legal aspect is another fundamental requirement
for cell-based therapy products. In China, the Guidelines
for Human Somatic Cell Therapies and Quality Control
of Cell-based Products stipulate that cell donation for
clinical applications must comply with national require-
ments the same as for blood donation. In America, the
Food and Drug Administration (FDA) “Tissue Donor
Guidance (2007)” states that the potential tissue donor
must test negative for a series of infectious microorgan-
isms prior to donation. Screening for tissue donors who
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have signed the informed consent is therefore an import-
ant step to ensure the suitability of the cells generated
from the donated tissue for clinical applications. After
explaining the significance and potential applications of
cells that would be generated from the donated tissue to
children undergoing foreskin resection surgery and their
parents, some patients and parents agreed to donate
their tissues and signed the informed consent. The cases
and medical reports of the patients were then strictly
evaluated to assess their eligibility for donation. Finally,
a 6-year-old boy’s foreskin tissue was chosen (Fig. 1).
Derivation of clinical-grade HFF cells
Serum-containing medium are often used for fibroblast
derivation and culture. To establish fibroblasts free of
animal-source reagents in our laboratory, several types
of Xeno-free or chemical defined human fibroblasts cul-
ture media were trialed (Data not shown). The result
showed that FibroGRO™ Xeno-Free Human Fibroblast
Expansion Medium provided the optimum support for
HFF cell growth. As a potential clinical-grade hiPSC and
Xeno-free feeder cell source, biosecurity of the HFF has
to be validated. In this case, a series of biosecurity-related
projects were carried out. The results of these projects are
presented in Additional file 2. The cell properties and
safety are validated by the NIFDC in China.
Derivation of clinical-grade hiPSCs
The clinical-grade HFF cells of passage 8 were used for
integration-free Sendai virus-based reprogramming. The
reprogramming procedure was similar to the instructions
of the CytoTune®-iPS Sendai Reprogramming Kit except
that Xeno-free media were used in our protocol. Pluriton™
reprogramming medium is a type of Xeno-free medium
which can efficiently support the generation of hiPSCs in
mRNA-based reprogramming. The X medium, which was
defined in our laboratory, could greatly improve the in-
duction efficiency of pig and human iPSCs [24, 26] and
could be configured with Xeno-free reagents. We pro-
posed that clinical-grade hiPSCs could also be efficiently
derived in pluriton™ reprogramming medium and X
medium, and thus both media were utilized in the repro-
gramming process. The hiPSC colonies emerged at day 12
after infection and were picked up 5 days later to generate
Fig 1 Overview of activities and requirements for clinical-grade hiPSC derivation and characterization. GMP good manufacturing practice,
iPSC induced pluripotent stem cell, NIFDC National Institutes for Food and Drug Control, BSA Bovine serum albumin
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stable cell lines (Fig. 2a). The reprogramming efficiency of
X medium was almost three times that of the pluriton™
reprogramming medium (data not shown).
Clinical-grade hiPSCs express specific pluripotency
markers
In total, 20 clinical-grade hiPSC lines were generated
and two random lines were selected for further
characterization. Both clinical-grade hiPSC lines exhib-
ited morphology consistent with that of hESCs and
could be subsequently passaged on clinical-grade HFF
feeder layers (Fig. 2b; and Figure S1A in Additional file
3). These cells expressed high levels of alkaline phos-
phatase (Fig. 2c; and Figure S1B in Additional file 3)
and maintained normal karyotypes when being charac-
terized at passage 20 (Fig. 2d; and Figure S1C in Add-
itional file 3). Real-time PCR results showed that the
two cell lines expressed pluripotent genes Oct4 (Pou5f1),
Sox2, Nanog, Rex1, and E-Cadherin at similar levels to
hESCs (Fig. 2e). Immunofluorescence results showed that
the two cell lines expressed pluripotency markers OCT4,
SOX2, SSEA-3, SSEA-4, and TRA-1-60 and did not ex-
press differentiation marker SSEA-1 (Fig. 2f; and Figure
S1D in Additional file 3).
Chemically defined E8 medium and vitronectin-coated
surfaces have been validated for the support of hiPSC cul-
ture. Therefore, to avoid hiPSC cell culture instability
stemming from variable human sourced albumin batches,
E8 medium and vitronectin-coated surfaces were used in
the culture of these two lines. Both lines grew well without
major differentiation in E8 medium (Fig. 2b, h; and Figure
S1A in Additional file 3). The percentages of SSEA-4,
TRA-1-60, and TRA-1-81 expression were higher than 90
%, whereas less than 1 % of SSEA-1 was expressed
(Fig. 2i).
PCR results showed that both lines were integration-
free (Fig. 2g) and all of the four Sendai virus vectors
were gradually lost in the cytoplasm (Fig. 2h).
Clinical-grade hiPSCs can differentiate into all three germ
layers
The EB and teratoma formation assays are commonly
used to evaluate the differentiation ability of hPSCs.
Both of the clinical-grade hiPSC lines were grown in
suspension in clinical-grade hESC basic medium. Eight
days later, they all formed round EBs (Fig. 3a; and Figure
S1E in Additional file 3). RT-PCR analysis showed that
the EBs expressed markers of all three germ layers, in-
cluding ectoderm (Gad1 and Pax6), mesoderm (Enolase
and Ostenectin), and endoderm (Nicastrin and Alpha-
fetoprotein) (Fig. 3b). The teratoma formation assay was
performed by injection of the two hiPSC lines to the
testis of SCID mice separately. Two months later, terato-
mas were visualized in all injected testes. Histological
analysis revealed that the teratomas comprised tissues of
all three germ layers (Fig. 3c; and Figure S1F in
Additional file 3).
Clinical-grade hiPSCs can directly differentiate to
functional neural cells and cardiomyocytes in Xeno-free
media
hPSCs including hESCs and hiPSCs cannot be used
directly in cell replacement therapies as they may in-
duce tumor formation. However, terminally differenti-
ated functional cells derived from hiPSCs can be used
for clinical applications. Therefore it is important to
evaluate the differentiation ability of our clinical-grade
hiPSCs into specific cell types under Xeno-free condi-
tions. Neural cell and cardiomyocyte differentiations
were chosen for this purpose.
For neural cell differentiation, hiPSCs were directed to
forebrain dopamine neurons following a series of spatial
and temporal specific signal inductions according to the
neural lineage development process [25]. Twenty-three
days after differentiation, the neurons expressed neural
marker TUJ1 and dopamine neural marker TH1 (Fig. 3d).
For cardiomyocyte differentiation, the Car-CDM
medium modified in our laboratory was used. The dif-
ferentiation process followed a temporal WNT signal
activation and inhibition as described previously [27].
Beating cardiomyocytes were visible 12 days after differen-
tiation and cardiomyocyte specific markers NKX2.5 and
CTNT were detected by immunofluorescence staining
(Fig. 3e).
Clinical-grade hiPSCs are biologically safe
To evaluate whether our clinical-grade hiPSCs are bio-
logically safe, we performed a series of tests according to
the Guidelines for Human Somatic Cell Therapies and
Quality Control of Cell-based Products. The results
showed that the cells were negative for mycoplasma and
free of serious pathogenic microorganisms such as HIV
and HPV (Additional file 2). The endotoxin level of the
hiPSC culture medium met the requirements defined in
the Pharmacopoeia of the People’s Republic of China,
2010 edition, Volume III (Additional file 2). To detect
other types of unknown pathogenic microorganisms, we
injected the hiPSCs into the chorioallantoic and yolk sac
of chicks. After 5 and 10 days of incubation separately,
the chicks were still alive (Additional file 2), which indi-
cated that the hiPSCs were not infected with pathogenic
microorganisms.
Discussion
Clinical-grade hiPSCs and GMP environments are es-
sential in order to ensure the safety, effectiveness,
traceability, and reproducibility of hiPSC-based clinical
trials or therapies [16, 28]. To avoid the risk of cross-
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species infectious agent transfer, the usage of animal-
source reagents in cell handling process is not recom-
mended [29].
The hESCs used in the clinical trials approved by the
US FDA as mentioned earlier were not derived under
GMP conditions. Instead they were converted from
research-grade lines which were derived and maintained
in the presence of animal products [28]. It is unclear
whether this protocol can be applied in hiPSCs. After all,
it is far easier to obtain cell sources for hiPSCs than for
hESCs. Recently, several groups reported that they have
successfully derived clinical-grade or Xeno-free hiPSCs.
However, the derivation of hiPSCs was not entirely
Xeno-free [21–23] or under GMP conditions [20]. To
our knowledge, our study is the first to report successful
derivation of clinical-grade hiPSC lines completely under
GMP conditions in Xeno-free reagents. These hiPSC
lines may be a valuable source for future clinical trials or
therapies.
Oncogenicity is a major concern for the application of
hiPSCs in clinical settings. Nevertheless, an increasing
number of studies in mouse models suggest that iPSCs
are safe for transplantation [30]. For example, Tsuji et al.
[30] have reported no tumor formation after the trans-
plantation of iPSC-derived neural spheres into SCID
mouse brain. The process of obtaining iPSCs is complex,
however, involving the reconstruction of cellular epigen-
etic states. Assessment of genomic integrity and epigen-
etic variations of hiPSCs is therefore very important to
ensure their safety. To date, the induction of genomic
and epigenetic variations in iPSCs is still questionable.
Hussein et al. [31] reported that there are more chromo-
somal copy number variations in iPSCs compared with
embryonic stem cells and their parental cells, while
Abyzov et al. [32] proved that reprogramming did not
lead to copy number variations using single-cell sequen-
cing. Interestingly, a few groups reported abnormal gen-
omic imprinting and methylation in iPSCs [33, 34]. The
quality of each iPSC line varies and thus it is important to
define a series of criteria from the genomic and epigenetic
level to evaluate the safety of the iPSCs before their clin-
ical application. This requires joined efforts from scientists
all over the world. The results of clinical trials in Japan will
give us some clues.
Reprogramming efficiency is another important factor
for future hiPSC-based therapies because parental cells
from old patients which are difficult to be reprogrammed
may be required. We compared the reprogramming effi-
ciency of two Xeno-free mediums and found that the
number of colonies yielded from X medium, defined in
our laboratory, are three times that from pluriton™ repro-
gramming medium, suggesting that our X medium could
be used as a high-efficiency clinical-grade reprogramming
medium.
Envisaging the potential translation from hiPSCs to
cell replacement therapies, Xeno-free and GMP condi-
tions are essential for the differentiation of hiPSCs into
functional cells. We demonstrated the feasibility of
differentiating one clinical-grade hiPSC line to functional
neurons and cardiomyocytes in Xeno-free mediums
according to the monolayer differentiation methods. As
for monolayer differentiation, each hPSC line has an op-
timal differentiation method, and hence further work will
be focused on optimizing the monolayer differentiation
method to obtain functional neurons, cardiomyocytes,
and other cell types from the clinical-grade hiPSC lines.
The incidence of degenerative diseases such as Parkin-
son’s disease and Alzheimer’s disease which cannot be
treated effectively by traditional medical methods is in-
creasing worldwide. Theoretically, replacement of degen-
erated cells with normal functional cells in patients
paves the way for new treatment strategies. hiPSCs can
provide an unlimited number of cells for autologous or
closely HLA-matched transplantation upon differentiation
which significantly reduces the risk of host immune re-
sponse in patients. Only by standardizing and normalizing
all processes during stem cell-based therapies can we
ensure therapy safety and obtain objective and reliable
results. These processes involve acquisition, cultivation,
characterization, and purification of stem cells, testing
tumorigenicity and immunogenicity of stem cells, in vivo
reinfusion, efficacy evaluation of stem cells, and so on.
In the near future, stem cell-based therapies will create
a landmark achievement in the field of regenerative
(See figure on previous page.)
Fig. 2 Reprogramming of clinical-grade HFF cells into clinical-grade hiPSCs and characterization of their pluripotency. a Time course of clinical-grade
hiPSC generation. b Morphology of clinical-grade HFF cells, and clinical-grade hiPSCs grown on HFF feeder cells and in feeder-free conditions. Scale
bar, 200 μm. c Clinical-grade hiPSCs express alkaline phosphatase. Scale bar, 200 μm. d Karyotyping results of one of the clinical-grade hiPSC
lines. e mRNA expression levels of pluripotency-related genes of the clinical-grade hiPSCs relative to hESCs. f Immunofluorescence results of
one of the clinical-grade hiPSC lines. The hiPSCs express pluripotency markers OCT4, SOX2, SSEA-3, SSEA-4, and TRA-1-60 at the protein level
and do not express differentiation marker SSEA-1. Scale bar, 100 μm. g PCR analysis results show that the clinical-grade hiPSCs did not express
Sendai virus exogenous genes. h PCR analysis results show that the Sendai virus genes did not integrate into the genomic of the clinical-grade
hiPSCs. i Flow cytometry analysis of SSEA-1, SSEA-4, TRA-1-60, and TRA-1-81 expression of one of the clinical-grade hiPSC lines growing without
feeders. D day, ESC embryonic stem cell, GMP good manufacturing practice, HFF human foreskin fibroblast, iPSC induced pluripotent stem cell, SSEA
stage-specific embryonic antigen
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medicine and provide the theoretical basis and technical
supports for conquering particular “human ills” by follow-
ing strict regulations.
Conclusions
hiPSCs hold great promise in regenerative medicine.
To ensure clinical safety and obtain reliable therapeutic
results, standardized and normalized processes must be
followed during hiPSC-based therapies. Herein, integration-
free clinical-grade hiPSC lines were derived under GMP-
controlled conditions and with Xeno-free reagent culture
in line with the current guidance of international and na-
tional evaluation criteria, and proved to be biologically
safe and capable of differentiating into functional neural
Fig 3 Clinical-grade hiPSCs can randomly differentiate into all three germ layers and directly differentiate into functional neural cells and
cardiomyocytes in Xeno-free media. a Morphology of EBs at day 8 derived from one clinical-grade hiPSC line. Scale bar, 200 μm. b Gene
expression profile for germ-layer marker genes of the day 8 EBs, ectoderm (Gad1 and Pax6), mesoderm (Enolase and Osteonectin), endoderm
(Nicastrin and Alpha-fetoprotein), and pluripotency (Oct4, Sox2 and Nanog). c Hematoxylin and eosin staining of teratoma derived from one
clinical-grade hiPSC line. Scale bar, 100 μm. The teratomas contain tissues of all three germ layers. d Immunofluorescence results of neural
cells differentiated from one clinical-grade hiPSC line. The neural cells express TH1 and TUJ1 at protein level. Scale bar, 100 μm. e Immunofluorescence
results of cardiomyocytes differentiated from one clinical-grade hiPSC line. The cardiomyocytes express NKX2.5 and CTNT at protein level. Scale bar,
100 μm. EB embryoid body, GMP good manufacturing practice, iPSC induced pluripotent stem cell
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cells and cardiomyocytes in Xeno-free culture media. These
results provide that the clinical-grade hiPSC lines could be
valuable sources for future hiPSC-based clinical trials or
therapies, especially in neural and heart-related diseases.
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Additional file 1: Table S1. Presenting primer sequences for RT-PCR.
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Additional file 3: Figure S1. Showing characterization of another
clinical-grade hiPSC line. A Morphology of one clinical-grade hiPSC grown
on human foreskin fibroblasts feeder cells and in feeder-free conditions.
Scale bar, 200 μm. B Clinical-grade hiPSCs express alkaline phosphatase.
Scale bar, 200 μm. C Karyotyping results of one clinical-grade hiPSC line.
D Immunofluorescence results of one clinical-grade hiPSC line. The
hiPSCs express pluripotency markers OCT4, SOX2, SSEA-3, SSEA-4, and
TRA-1-60 at the protein level and do not express differentiation marker
SSEA-1. SSEA stage-specific embryonic antigen. Scale bar, 100 μm. E
Morphology of EBs at day 8 derived from one clinical-grade hiPSC line.
Scale bar, 200 μm. F Hematoxylin and eosin staining of teratoma derived
from one clinical-grade hiPSC line. Scale bar, 100 μm. The teratomas
contain tissues of all three germ layers. (TIFF 9074 kb)
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